AbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn’s and Colitis Organisation (ECCO)
AbbVie announced new data on upadacitinib (RINVOQ) in ulcerative colitis and risankizumab (SKYRIZI) in Crohn’s disease will be presented as oral presentations at the 16th Congress of European Crohn’s and Colitis Organisation (ECCO), to be held virtually July 2-3 and July 8-10. AbbVie is presenting a total of nine abstracts, five of which are oral presentations, across a broad range of studies in inflammatory bowel diseases (IBD).
“We know many people with IBD are still suffering with the debilitating effects of their disease,” said Remo Panaccione, M.D., professor of medicine and director of the IBD unit, University of Calgary. “AbbVie’s robust research on display at ECCO highlights meaningful developments that have the potential to positively impact the lives and improve the standards of care for people living with gastrointestinal diseases, including ulcerative colitis and Crohn’s disease.”
Two separate oral presentations will feature data from the pivotal Phase 3 induction studies evaluating the efficacy and safety of upadacitinib (45 mg, once daily) as induction therapy in patients with moderate to severe ulcerative colitis. These studies, U-ACHIEVE and U-ACCOMPLISH, will highlight the impact of upadacitinib on clinical, endoscopic and histologic outcomes after 8 weeks of treatment. Top-line results from these studies were previously announced in December 2020 and February 2021, respectively.
Data from the global Phase 3 program evaluating risankizumab in adults with moderate to severe Crohn’s disease will be presented as three separate oral presentations. Phase 3 induction studies, ADVANCE and MOTIVATE, for risankizumab (600 mg or 1200 mg) evaluated clinical remission and response and improvements in endoscopic outcomes at week 12. The third oral presentation from ADVANCE AND MOTIVATE will highlight the impact of risankizumab induction therapy on patient-reported outcomes. Top-line results from these studies were previously announced in January 2021.
In addition, several presentations will focus on advancing research surrounding the importance of understanding patient preferences and the impact of patient-reported outcomes. In partnership with the European Federation of Crohn’s & Ulcerative Colitis Associations (EFCCA), AbbVie will present results from the P-POWER IBD study that evaluated clinical outcomes and challenges in patients with IBD.
“This study investigated how difficult it is for patients to manage their IBD,” said Salvo Leone, chairman of EFCCA. “Patients are seeking further treatment options to control the unpredictability of this disease and its debilitating impact on their daily lives.”
Results from the ICONIC study will also be presented, evaluating the correlation between patient-reported outcomes and patient-reported disease activity in ulcerative colitis.